DEF 14A: Day One Biopharmaceuticals Announces 2024 Annual Meeting of Stockholders

Day One Biopharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of future executive compensation votes.

Summary

• Day One Biopharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024.
• Stockholders will vote on the election of three Class III directors for three-year terms.
• The meeting will also include a vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• An advisory vote will be held on the compensation of the company's named executive officers.
• Stockholders will also vote on the frequency of future advisory votes on executive compensation, with options for every one, two, or three years.
• The record date for determining stockholders eligible to vote is March 28, 2024.
• The board of directors recommends voting for the election of all director nominees, for the ratification of PwC, for the approval of executive compensation, and for holding future advisory votes on executive compensation every one year.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company highlights its commitment to good corporate governance and competitive compensation, contributing to a moderately positive sentiment.

Positives

• The company is committed to good corporate governance, with a majority of independent directors (9 out of 10).
• The board leadership structure separates the chairperson and CEO roles.
• All committees of the board are composed of independent directors.
• The board is focused on enhancing diversity and refreshment.
• The company has comprehensive risk oversight practices, including cybersecurity and data privacy.
• The nominating and corporate governance committee oversees corporate responsibility and sustainability programs.
• Independent directors conduct regular executive sessions.
• The company has related party transaction standards.
• The company offers competitive pay and benefits, including equity compensation, for all full-time employees.
• The company emphasizes employee development and training.

Risks

• The document includes forward-looking statements that are subject to risks, assumptions, estimates, and uncertainties.
• The company's future results and financial condition could be affected by various risk factors detailed in their Annual Report on Form 10-K.

Future Outlook

The proxy statement includes forward-looking statements regarding future operating results, financial condition, business strategy, market growth, and objectives for future operations, all of which are subject to risks and uncertainties.

Management Comments

• Jeremy Bender, Chief Executive Officer and President, encourages stockholders to read the proxy statement and vote their shares.
• The board of directors believes that its independence and oversight of management is maintained effectively through its leadership structure, the composition of the board of directors and sound corporate governance policies and practices.

Industry Context

This announcement is a standard part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• The company's corporate governance practices, such as having a majority of independent directors and separate chairperson and CEO roles, align with best practices observed in similar biotechnology companies.
• The executive compensation program, including the use of stock options and RSUs, is consistent with practices among peer companies in the biotechnology industry.
• The company's risk oversight practices, including cybersecurity and data privacy, are increasingly important in the biotechnology industry, given the sensitive nature of patient data and intellectual property.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting on key proposals.
• Employees are impacted by the company's compensation policies and corporate responsibility initiatives.
• The company's commitment to ethical practices and compliance with regulations benefits all stakeholders.

Next Steps

• Stockholders should review the proxy statement and vote their shares before the deadlines.
• The company will hold the Annual Meeting on May 23, 2024, and announce the voting results.

Key Dates

Keywords

stockholders, directors, compensation, governance, proxy, meeting, audit, executive, PwC, vote, Day One Biopharmaceuticals